Israel - English - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 2 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - English - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 3 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - English - Ministry of Health

unipharm ltd, israel - risperidone - coated tablets - risperidone 4 mg - risperidone - risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. the antipsychotic efficacy of risperidone was established in short-term (6 to 8-weeks) controlled trials of schizophrenic inpatients. risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. conduct and other disruptive disorders: treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment-requiring behavioral disorders with reduced or substandard intelligence. treatment should not be given to children under the age of 5 years.risperidone is indicated for the treatment of mania in bipolar disorder. these episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors

Israel - English - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 100 mg - losartan - hypertension: lotan 100 is indicated for the treatment of hypertension. heart failure:lotan 100 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 100 is not recommended. renal protection in type-2 diabetic patients with proteinuria: lotan 100 is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 100 is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of lotan 100 on the

Israel - English - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 12.5 mg - losartan - heart failure: lotan 12.5 is indicated for the treatment of heart failure, when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to lotan 12.5 mg is not recommended

Israel - English - Ministry of Health

unipharm ltd, israel - losartan potassium - tablets - losartan potassium 50 mg - losartan - hypertension: lotan 50 mg is indicated for the treatment of hypertensionheart failure: lotan 50 mg is indicated for the treatment of heart failure, usually in addition to diuretics and/or digitalis, if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to lotan 50 mg is not recommended.renal protection in type-2 diabetic patients with proteinuria: lotan 50 mg is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. lotan 50 mg is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventri

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; lactic acid as sodium 1.68 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 13.6 g/l; calcium chloride dihydrate 0.184 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; glucose monohydrate (as anhydrous) 22.7 g/l; calcium chloride dihydrate 0.184 g/l; lactic acid as sodium 1.68 g/l; magnesium chloride hexahydrate 0.051 g/l; sodium bicarbonate 2.10 g/l - sodium chloride - sodium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure severe water retention severe electrolyte imbalance drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; glucose monohydrate (as anhydrous); lactic acid as sodium; magnesium chloride hexahydrate; sodium bicarbonate; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.38 g/l; magnesium chloride hexahydrate 0.051 g/l; calcium chloride dihydrate 0.184 g/l; sodium bicarbonate 2.10 g/l; glucose monohydrate (as anhydrous) 38.6 g/l; lactic acid as sodium 1.68 g/l - calcium chloride - calcium chloride - physioneal is indicated whenever peritoneal dialysis is employed including:acute and chronic renal failure; severe water retention; severe electrolyte imbalance; drug intoxication with dialysable substances when a more adequate therapeutic alternative is not available. bicarbonate/lactate based physioneal peritoneal dialysis solutions with a physiological ph are particularly indicated in patients in whom solutions based on lactate buffer only with a low ph cause abdominal inflow pain or discomfort.

Israel - English - Ministry of Health

unipharm ltd, israel - amlodipine as besilate; valsartan - coated tablets - valsartan 160 mg; amlodipine as besilate 10 mg - valsartan - treatment of essential hypertension. duplex is indicated for patients whose blood pressure is not adequately controlled on monotherapy.